ES2914082T3 - Procedimiento de generación de progenitores de células T - Google Patents
Procedimiento de generación de progenitores de células T Download PDFInfo
- Publication number
- ES2914082T3 ES2914082T3 ES15771979T ES15771979T ES2914082T3 ES 2914082 T3 ES2914082 T3 ES 2914082T3 ES 15771979 T ES15771979 T ES 15771979T ES 15771979 T ES15771979 T ES 15771979T ES 2914082 T3 ES2914082 T3 ES 2914082T3
- Authority
- ES
- Spain
- Prior art keywords
- cells
- fragment
- ligand
- fibronectin
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title claims abstract description 58
- 238000000034 method Methods 0.000 title claims abstract description 53
- 210000004027 cell Anatomy 0.000 claims abstract description 133
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims abstract description 82
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims abstract description 82
- 239000003446 ligand Substances 0.000 claims abstract description 77
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 44
- 108010067306 Fibronectins Proteins 0.000 claims abstract description 43
- 239000012634 fragment Substances 0.000 claims abstract description 43
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 34
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229960002897 heparin Drugs 0.000 claims abstract description 12
- 229920000669 heparin Polymers 0.000 claims abstract description 12
- 238000000338 in vitro Methods 0.000 claims abstract description 10
- 102000016359 Fibronectins Human genes 0.000 claims abstract 8
- 102000004127 Cytokines Human genes 0.000 claims description 18
- 108090000695 Cytokines Proteins 0.000 claims description 18
- 210000000130 stem cell Anatomy 0.000 claims description 16
- 108010041111 Thrombopoietin Proteins 0.000 claims description 14
- 102000036693 Thrombopoietin Human genes 0.000 claims description 13
- 239000013603 viral vector Substances 0.000 claims description 13
- 108010002586 Interleukin-7 Proteins 0.000 claims description 11
- 239000003102 growth factor Substances 0.000 claims description 11
- 229940100994 interleukin-7 Drugs 0.000 claims description 11
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 claims description 4
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 claims description 4
- -1 SCF Proteins 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 101001027128 Homo sapiens Fibronectin Proteins 0.000 claims description 2
- 230000003750 conditioning effect Effects 0.000 claims description 2
- 102000000704 Interleukin-7 Human genes 0.000 claims 3
- 238000001890 transfection Methods 0.000 claims 1
- NNRFRJQMBSBXGO-CIUDSAMLSA-N (3s)-3-[[2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-4-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-oxobutanoic acid Chemical group NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O NNRFRJQMBSBXGO-CIUDSAMLSA-N 0.000 abstract description 20
- 101000829980 Homo sapiens Ral guanine nucleotide dissociation stimulator Proteins 0.000 abstract description 5
- 102100023320 Ral guanine nucleotide dissociation stimulator Human genes 0.000 abstract description 5
- 108010070047 Notch Receptors Proteins 0.000 description 57
- 102000005650 Notch Receptors Human genes 0.000 description 57
- 102100037362 Fibronectin Human genes 0.000 description 35
- 108010056030 retronectin Proteins 0.000 description 22
- 230000004069 differentiation Effects 0.000 description 21
- 239000002609 medium Substances 0.000 description 20
- 108090000765 processed proteins & peptides Proteins 0.000 description 20
- 101710178046 Chorismate synthase 1 Chemical group 0.000 description 17
- 101710152695 Cysteine synthase 1 Chemical group 0.000 description 17
- 102100032831 Protein ITPRID2 Human genes 0.000 description 17
- 239000002243 precursor Substances 0.000 description 16
- 210000004700 fetal blood Anatomy 0.000 description 13
- 239000001963 growth medium Substances 0.000 description 10
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 10
- 230000037361 pathway Effects 0.000 description 10
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 9
- 230000026683 transduction Effects 0.000 description 9
- 238000010361 transduction Methods 0.000 description 9
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 8
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 8
- 102100021592 Interleukin-7 Human genes 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 238000004113 cell culture Methods 0.000 description 8
- 239000012091 fetal bovine serum Substances 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 206010061598 Immunodeficiency Diseases 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 108010089975 arginyl-glycyl-aspartyl-serine Proteins 0.000 description 7
- 108020001507 fusion proteins Proteins 0.000 description 7
- 102000037865 fusion proteins Human genes 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- 102100039064 Interleukin-3 Human genes 0.000 description 6
- 108010002386 Interleukin-3 Proteins 0.000 description 6
- 239000011324 bead Substances 0.000 description 6
- 108010044426 integrins Proteins 0.000 description 6
- 102000006495 integrins Human genes 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000002054 transplantation Methods 0.000 description 6
- 208000029462 Immunodeficiency disease Diseases 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- 210000000173 T-lymphoid precursor cell Anatomy 0.000 description 5
- 210000001185 bone marrow Anatomy 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 238000001415 gene therapy Methods 0.000 description 5
- 230000007813 immunodeficiency Effects 0.000 description 5
- 102000018358 immunoglobulin Human genes 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 4
- 108700019146 Transgenes Proteins 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 4
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 4
- 208000024908 graft versus host disease Diseases 0.000 description 4
- 229940076264 interleukin-3 Drugs 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 241001529936 Murinae Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000007640 basal medium Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 238000003501 co-culture Methods 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 108700041286 delta Proteins 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000001177 retroviral effect Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- 102100022983 B-cell lymphoma/leukemia 11B Human genes 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 101000872077 Homo sapiens Delta-like protein 4 Proteins 0.000 description 2
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 2
- 101001105486 Homo sapiens Proteasome subunit alpha type-7 Proteins 0.000 description 2
- 101001047681 Homo sapiens Tyrosine-protein kinase Lck Proteins 0.000 description 2
- 102100025304 Integrin beta-1 Human genes 0.000 description 2
- 102100039824 Pre T-cell antigen receptor alpha Human genes 0.000 description 2
- 102100021201 Proteasome subunit alpha type-7 Human genes 0.000 description 2
- 102100030627 Transcription factor 7 Human genes 0.000 description 2
- 102100024036 Tyrosine-protein kinase Lck Human genes 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 210000004504 adult stem cell Anatomy 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000009395 genetic defect Effects 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 230000002138 osteoinductive effect Effects 0.000 description 2
- 101150083745 preT gene Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000002992 thymic effect Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000029483 Acquired immunodeficiency Diseases 0.000 description 1
- 201000011452 Adrenoleukodystrophy Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 101710145993 B-cell lymphoma/leukemia 11B Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101100421200 Caenorhabditis elegans sep-1 gene Proteins 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 102100033553 Delta-like protein 4 Human genes 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000903697 Homo sapiens B-cell lymphoma/leukemia 11B Proteins 0.000 description 1
- 101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 description 1
- 101000994369 Homo sapiens Integrin alpha-5 Proteins 0.000 description 1
- 101001043809 Homo sapiens Interleukin-7 receptor subunit alpha Proteins 0.000 description 1
- 101000972291 Homo sapiens Lymphoid enhancer-binding factor 1 Proteins 0.000 description 1
- 101000606310 Homo sapiens Pre T-cell antigen receptor alpha Proteins 0.000 description 1
- 101000819111 Homo sapiens Trans-acting T-cell-specific transcription factor GATA-3 Proteins 0.000 description 1
- 101000653540 Homo sapiens Transcription factor 7 Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 102100032818 Integrin alpha-4 Human genes 0.000 description 1
- 102100032817 Integrin alpha-5 Human genes 0.000 description 1
- 102100021593 Interleukin-7 receptor subunit alpha Human genes 0.000 description 1
- 108700003486 Jagged-1 Proteins 0.000 description 1
- 102000004857 Lymphoid enhancer-binding factor 1 Human genes 0.000 description 1
- 102100022699 Lymphoid enhancer-binding factor 1 Human genes 0.000 description 1
- 108090001093 Lymphoid enhancer-binding factor 1 Proteins 0.000 description 1
- 101001043810 Macaca fascicularis Interleukin-7 receptor subunit alpha Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101100351020 Mus musculus Pax5 gene Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102100023181 Neurogenic locus notch homolog protein 1 Human genes 0.000 description 1
- 108700037638 Neurogenic locus notch homolog protein 1 Proteins 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 102100035593 POU domain, class 2, transcription factor 1 Human genes 0.000 description 1
- 101710084414 POU domain, class 2, transcription factor 1 Proteins 0.000 description 1
- 101710129866 Pre T-cell antigen receptor alpha Proteins 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102100032702 Protein jagged-1 Human genes 0.000 description 1
- 108700037966 Protein jagged-1 Proteins 0.000 description 1
- 102100032733 Protein jagged-2 Human genes 0.000 description 1
- 101710170213 Protein jagged-2 Proteins 0.000 description 1
- 102000001183 RAG-1 Human genes 0.000 description 1
- 108060006897 RAG1 Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108010088184 T Cell Transcription Factor 1 Proteins 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 208000002903 Thalassemia Diseases 0.000 description 1
- 102100034195 Thrombopoietin Human genes 0.000 description 1
- 102100021386 Trans-acting T-cell-specific transcription factor GATA-3 Human genes 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 101710123661 Venom allergen 5 Proteins 0.000 description 1
- 208000010796 X-linked adrenoleukodystrophy Diseases 0.000 description 1
- 101100351021 Xenopus laevis pax5 gene Proteins 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009141 biological interaction Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000008045 co-localization Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 108700014844 flt3 ligand Proteins 0.000 description 1
- 238000011990 functional testing Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000034737 hemoglobinopathy Diseases 0.000 description 1
- 102000022382 heparin binding proteins Human genes 0.000 description 1
- 108091012216 heparin binding proteins Proteins 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000018337 inherited hemoglobinopathy Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/42—Notch; Delta; Jagged; Serrate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/1114—T cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/52—Fibronectin; Laminin
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1459539A FR3026744B1 (fr) | 2014-10-06 | 2014-10-06 | Methode de generation de progeniteurs de cellules t |
| PCT/EP2015/072889 WO2016055396A1 (fr) | 2014-10-06 | 2015-10-05 | Méthode de génération de progéniteurs de cellules t |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES2914082T3 true ES2914082T3 (es) | 2022-06-07 |
| ES2914082T8 ES2914082T8 (es) | 2022-06-16 |
Family
ID=52102849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES15771979T Active ES2914082T3 (es) | 2014-10-06 | 2015-10-05 | Procedimiento de generación de progenitores de células T |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12071635B2 (enExample) |
| EP (2) | EP3204492B1 (enExample) |
| JP (2) | JP6898240B2 (enExample) |
| CA (1) | CA2963756C (enExample) |
| DK (1) | DK3204492T3 (enExample) |
| ES (1) | ES2914082T3 (enExample) |
| FR (1) | FR3026744B1 (enExample) |
| HU (1) | HUE059468T2 (enExample) |
| PL (1) | PL3204492T3 (enExample) |
| PT (1) | PT3204492T (enExample) |
| WO (1) | WO2016055396A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3440198A4 (en) | 2016-04-08 | 2019-11-06 | The Governing Council of the Universtiy of Toronto | PROCESS FOR THE PRODUCTION OF PRE-TREATMENT T CELLS FROM TRUNK AND / OR PRECURSOR CELLS AND USE THEREOF |
| IL268641B2 (en) * | 2017-02-13 | 2024-10-01 | Assist Publique Hopitaux Paris Aphp | Method for generating t cells progenitors |
| CN112041431A (zh) * | 2018-02-14 | 2020-12-04 | 桑尼布鲁克研究所 | 产生t细胞谱系细胞的方法 |
| FR3079239A1 (fr) * | 2018-03-23 | 2019-09-27 | Centre National De La Recherche Scientifique | Nouvelle methode d’obtention de cellules t a partir de cellules souches pluripotentes, et leurs utilisations |
| EP3774867A1 (en) * | 2018-04-10 | 2021-02-17 | Stichting Sanquin Bloedvoorziening | Chimeric notch receptors |
| JP2023553313A (ja) | 2020-11-30 | 2023-12-21 | チョ ファーマ インコーポレイテッド | 細胞を富化するための抗体 |
| EP4426319A1 (en) | 2021-11-04 | 2024-09-11 | APHP (Assistance Publique - Hôpitaux de Paris) | Method for generating nk cells |
| WO2024175738A1 (en) | 2023-02-22 | 2024-08-29 | Smart Immune | Method for thymus regeneration |
| WO2025012449A1 (en) | 2023-07-12 | 2025-01-16 | Smart Immune | Biobank of cellular banks having specific homozygous hla haplotypes and uses thereof for treating patients |
| WO2025219552A1 (en) | 2024-04-17 | 2025-10-23 | Assitance Publique Hopitaux De Paris | Method for producing t cell progenitors from human pluripotent stem cells |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6093531A (en) | 1997-09-29 | 2000-07-25 | Neurospheres Holdings Ltd. | Generation of hematopoietic cells from multipotent neural stem cells |
| JP2001525176A (ja) | 1997-12-04 | 2001-12-11 | デューク・ユニバーシティー | Ｃｄ７＋ｃｄ３４−ｌｉｎ−造血細胞を単離し、使用する方法 |
| EA012520B1 (ru) * | 2003-08-22 | 2009-10-30 | Такара Био Инк. | Способ получения цитотоксических лимфоцитов |
| US10059923B2 (en) | 2008-01-30 | 2018-08-28 | Memorial Sloan Kettering Cancer Center | Methods for off-the-shelf tumor immunotherapy using allogeneic T-cell precursors |
| RU2535966C2 (ru) | 2008-09-12 | 2014-12-20 | Криопрашис Криобиоложия Лтда. | Клеточная терапия ишемической ткани |
| US8772028B2 (en) | 2008-11-07 | 2014-07-08 | Sunnybrook Health Sciences Centre | CD34+CD7+CD5+CD1a-human progenitor T-cells produced in vitro and methods of using |
| WO2011068962A1 (en) * | 2009-12-03 | 2011-06-09 | The University Of Utah Research Foundation | Methods for generating t lymphocytes from hematopoietic stem cells |
| US20130095079A1 (en) | 2010-04-09 | 2013-04-18 | Fred Hutchinson Cancer Research Center | Compositions and methods for providing hematopoietic function without hla matching |
| WO2013074916A1 (en) | 2011-11-18 | 2013-05-23 | Board Of Regents, The University Of Texas System | Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla |
| US9834755B2 (en) | 2011-12-08 | 2017-12-05 | Fred Hutchinson Cancer Research Center | Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells |
| WO2014110353A1 (en) * | 2013-01-11 | 2014-07-17 | The Trustees Of The University Of Pennsylvania | Notch ligand bound bicompatible substrates and their use in bone formation |
| EP3027755B1 (en) | 2013-08-02 | 2019-10-09 | The Regents of The University of California | Engineering antiviral t cell immunity through stem cells and chimeric antigen receptors |
| US20170128556A1 (en) | 2013-12-26 | 2017-05-11 | Thyas Co. Ltd. | Immunotherapy using t precursor cells derived from pluripotent stem cells having rearranged t cell receptor genes |
| KR20160145802A (ko) | 2014-04-23 | 2016-12-20 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 요법에 사용하기 위한 키메라 항원 수용체 (car) 및 이의 제조 방법 |
| US10131876B2 (en) | 2014-04-24 | 2018-11-20 | Miltenyi Biotec Gmbh | Method for automated generation of genetically modified T cells |
| WO2016039933A1 (en) * | 2014-09-11 | 2016-03-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Lentiviral vector for treating hemoglobin disorders |
-
2014
- 2014-10-06 FR FR1459539A patent/FR3026744B1/fr active Active
-
2015
- 2015-10-05 ES ES15771979T patent/ES2914082T3/es active Active
- 2015-10-05 EP EP15771979.0A patent/EP3204492B1/fr active Active
- 2015-10-05 WO PCT/EP2015/072889 patent/WO2016055396A1/fr not_active Ceased
- 2015-10-05 US US15/516,731 patent/US12071635B2/en active Active
- 2015-10-05 JP JP2017537016A patent/JP6898240B2/ja active Active
- 2015-10-05 PL PL15771979.0T patent/PL3204492T3/pl unknown
- 2015-10-05 PT PT157719790T patent/PT3204492T/pt unknown
- 2015-10-05 EP EP22152734.4A patent/EP4036224A1/fr not_active Withdrawn
- 2015-10-05 DK DK15771979.0T patent/DK3204492T3/da active
- 2015-10-05 HU HUE15771979A patent/HUE059468T2/hu unknown
- 2015-10-05 CA CA2963756A patent/CA2963756C/fr active Active
-
2020
- 2020-12-17 JP JP2020209370A patent/JP2021072779A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3204492A1 (fr) | 2017-08-16 |
| WO2016055396A1 (fr) | 2016-04-14 |
| ES2914082T8 (es) | 2022-06-16 |
| US20180208895A1 (en) | 2018-07-26 |
| PL3204492T3 (pl) | 2022-07-25 |
| EP4036224A1 (fr) | 2022-08-03 |
| HUE059468T2 (hu) | 2022-12-28 |
| FR3026744A1 (fr) | 2016-04-08 |
| EP3204492B1 (fr) | 2022-03-09 |
| CA2963756C (fr) | 2024-01-02 |
| JP2021072779A (ja) | 2021-05-13 |
| US12071635B2 (en) | 2024-08-27 |
| DK3204492T3 (da) | 2022-06-07 |
| PT3204492T (pt) | 2022-05-30 |
| CA2963756A1 (fr) | 2016-04-14 |
| JP6898240B2 (ja) | 2021-07-07 |
| JP2017531448A (ja) | 2017-10-26 |
| FR3026744B1 (fr) | 2024-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2914082T3 (es) | Procedimiento de generación de progenitores de células T | |
| US11642376B2 (en) | Method for generating T cell progenitors | |
| ES2396447T3 (es) | Proceso para producir linfocitos citotóxicos | |
| CN107922925A (zh) | 用于自然杀伤细胞扩增的方法 | |
| US12018276B2 (en) | Lymphocyte production method | |
| HK40081656A (en) | Method for generating t cells progenitors | |
| RU2797260C2 (ru) | Способ получения предшественников т-клеток | |
| WO2025094915A1 (ja) | 細胞傷害性ｔ細胞の製造方法 | |
| HK40017982B (en) | Method for generating t cells progenitors | |
| HK40017982A (en) | Method for generating t cells progenitors |